KYTRIL 1MG/1ML 1 MG
GRANISETRON (GRANISETRON HYDROCHLORIDE) : 1 MG · DIN 02088371 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: CANCELLED POST MARKET
What is KYTRIL 1MG/1ML?
KYTRIL 1MG/1ML 1 MG contains GRANISETRON (GRANISETRON HYDROCHLORIDE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02088371, held by HOFFMANN-LA ROCHE LIMITED, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 06-Jan-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KYTRIL 1MG/1ML used for?
Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy and radiation; prevention and treatment of postoperative nausea and vomiting.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02088371 |
|---|---|
| Brand name | KYTRIL 1MG/1ML |
| Generic / active ingredient | GRANISETRON (GRANISETRON HYDROCHLORIDE) : 1 MG |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 1 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | A04AA02 GRANISETRON |
| AHFS class | 56:22.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Jan-2012 |
| Original market date | 1996-12-31 00:00:00 |
How is it administered?
Chemotherapy: 10 mcg/kg IV over 5 min or 2 mg oral daily. Radiation: 2 mg oral daily. Postop: 1 mg IV over 30 seconds. Administer before chemotherapy/radiation/anesthesia.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section), but mentions dilution stability in specific solutions.
How is it supplied?
1 mg and 2 mg tablets; 1 mg/mL injection in 1 mL and 4 mL vials.
Contraindications
Contraindicated in patients with a known hypersensitivity to the drug or to any component of its formulations.
Warnings and precautions
Increased hepatocellular tumours in rodents (do not exceed dose). Cases of ECG modifications including QT prolongation. May mask progressive ileus or gastric distention.
Is GRANISETRON in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A04AA02 GRANISETRON. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-GRANISETRON | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02308894 |
| GRANISETRON HYDROCHLORIDE INJECTION | 1 MG | LIQUID | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02322765 |
| NAT-GRANISETRON | 1 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02452359 |
| GRANISETRON HYDROCHLORIDE INJECTION | 1 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02304708 |
| GRANISETRON HYDROCHLORIDE INJECTION | 1 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02384108 |
| GRANISETRON HYDROCHLORIDE INJECTION SDZ | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02385414 |
| GRANISETRON HYDROCHLORIDE INJECTION USP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | APPROVED | DIN 02558408 |
| JAMP GRANISETRON | 1 MG | TABLET | JAMP PHARMA CORPORATION | DORMANT | DIN 02472686 |
| KYTRIL TABLETS 1MG | 1 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02185881 |
Who else supplies GRANISETRON worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GRANISETRON appears in 56 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.